Telomir Pharmaceuticals (TELO) Institutional Ownership $4.24 -0.23 (-5.15%) (As of 11/22/2024 ET) Add Compare Share Share Ownership Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Institutional Ownership Changes (13F Filings) for Telomir Pharmaceuticals (NASDAQ:TELO)Number ofInstitutional Buyers(last 12 months)6TotalInstitutional Inflows(last 12 months)$1.88MNumber ofInstitutional Sellers(last 12 months)0 Get TELO Insider Trade Alerts Want to know when executives and insiders are buying or selling Telomir Pharmaceuticals stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data TELO Institutional Buying and Selling by Quarter Ad WealthPressI hate to say I told you soLast month, I openly declared that a Trump Presidency was going to kick off Tesla’s New Bullish Cycle Folks who listened and bought in when I said to are currently crushing it. As a matter of fact, all the trades we’ve opened ever since I made that public declaration have ALL been winners. And it’s simply because this Tesla indicator just flipped green on the stock…Follow this link right away. Telomir Pharmaceuticals Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails11/19/2024 Barclays PLC7,018$45K0.0%+325.1%0.024% 11/16/2024 Geode Capital Management LLC238,737$1.53M0.0%+259.8%0.806% 11/15/2024 Barclays PLC7,018$45K0.0%+325.1%0.024% 11/15/2024 State Street Corp36,094$232K0.0%+99.1%0.122% 10/21/2024 Suncoast Equity Management51,194$329K0.0%+109.9%0.173% 8/15/2024Beaird Harris Wealth Management LLC14,623$70K0.0%+212.9%0.049% 7/26/2024 Bank of New York Mellon Corp50,165$241K0.0%N/A0.169% 5/2/2024 Suncoast Equity Management24,391$126K0.0%N/A0.082% (Data available from 1/1/2016 forward) TELO Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of TELO shares? During the previous two years, the following institutional investors and hedge funds held shares of Telomir Pharmaceuticals shares: Geode Capital Management LLC ($1.53M), Suncoast Equity Management ($329K), Bank of New York Mellon Corp ($241K), State Street Corp ($232K), and Beaird Harris Wealth Management LLC ($70K), Barclays PLC ($45K).Learn more on TELO's institutional investors. Which institutional investors have been buying Telomir Pharmaceuticals stock? The following institutional investors have purchased Telomir Pharmaceuticals stock in the last 24 months: Geode Capital Management LLC ($172.38K), Suncoast Equity Management ($51.19K), Bank of New York Mellon Corp ($50.17K), State Street Corp ($17.97K), Barclays PLC ($10.73K), and Beaird Harris Wealth Management LLC ($9.95K). How much institutional buying is happening at Telomir Pharmaceuticals? Institutional investors have bought a total of 312,392 shares in the last 24 months. This purchase volume represents approximately $1.88M in transactions. Related Companies IGM Biosciences Major Shareholders Sana Biotechnology Major Shareholders PureTech Health Major Shareholders Mereo BioPharma Group Major Shareholders Monte Rosa Therapeutics Major Shareholders ProKidney Major Shareholders GH Research Major Shareholders Zevra Therapeutics Major Shareholders Esperion Therapeutics Major Shareholders Terns Pharmaceuticals Major Shareholders This page (NASDAQ:TELO) was last updated on 11/23/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telomir Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Telomir Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TELO Stock Alerts